← Patent-cliff monitor small molecule JAYPIRCA PIRTOBRUTINIB
Loss of exclusivity September 2041 latest FDA-listed patent expiry
Drug detail Brand name JAYPIRCA Active ingredient PIRTOBRUTINIB Strength 50MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval January 2023 Marketing status RX
Listed patents Patent Expires Type 12109193 September 2041 product 12268666 July 2039 product 10464905 December 2036 use U-4362 10918622 December 2036 use U-4362 10342780 December 2036 substance, product 12220401 December 2036 substance, product 10695323 December 2036 substance, product
Regulatory exclusivity Code Expires ODE-518 December 2032 ODE-451 December 2030 ODE-424 January 2030 I-981 December 2028 NCE January 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.